Discover
DNLI
Denali Therapeutics Inc.
24.69
1 x 24.20
1 x 25.18
bid
ask
-
0.31
1.24%
23 @ 04:00 PM
25.06 +0.37 (1.50%)
| Ytd | 49.55% | |
| 1y | 77.37% |
24.59
day range
25.29
12.58
52 week range
27.30
| Open | 25.07 | Prev Close | 25.00 | Low | 24.59 | High | 25.29 | Mkt Cap | 3.92B |
| Vol | 0.00 | Avg Vol | 1.85M | EPS | -2.88 | P/E | -8.57 | Forward P/E | -10.31 |
| Beta | 1.01 | Short Ratio | 7.65 | Inst. Own | 105.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 23.48 | 200-d Avg | 20.07 | 1yr Est | 34.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-05 | 2026-09 | -0.72 | N/A | N/A | N/A |
| 2026-08-06 | 2026-06 | -0.51 | -0.68 | -0.17 | -32.54% |
| 2026-05-07 | 2026-03 | -0.73 | -0.69 | 0.04 | 5.48% |
| 2026-02-26 | 2025-12 | -0.75 | -0.73 | 0.02 | 2.67% |
| 2025-11-06 | 2025-09 | -0.76 | -0.74 | 0.02 | 2.63% |
| 2025-08-11 | 2025-06 | -0.74 | -0.72 | 0.02 | 2.70% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-07 | UBS | Upgrade | Buy | Buy |
| 2026-07-23 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-07-16 | Deutsche Bank | Upgrade | Buy | Buy |
| 2026-05-26 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-05-14 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-05-11 | BTIG | Upgrade | Buy | Buy |
Profile
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-02 | BAKER BROS ADVISORS, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
| 2026-06-02 | FLATLEY JAY T | Director | 358.94K | Stock Award(Grant) |
| 2025-08-12 | HO CAROLE | Officer | 424.80K | Sale |
| 2026-06-02 | KLEIN PETER S | Director | 33.94K | Stock Award(Grant) |
| 2026-06-02 | KROGNES STEVE E | Director | 820.00K | Stock Award(Grant) |
| 2025-01-01 | SATO VICKI LEE | Director | 107.98K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Blackrock Inc. | 14.03M | 346.31M | 8.77% |
| 2026-06-29 | BAILLIE GIFFORD & CO | 11.96M | 295.30M | 7.48% |
| 2026-03-30 | T. Rowe Price Investment Management, Inc. | 8.52M | 210.34M | 5.33% |
| 2026-06-29 | State Street Corporation | 7.05M | 174.05M | 4.41% |
| 2026-06-29 | Temasek Holdings (Private) Ltd | 7.01M | 173.15M | 4.39% |
| 2026-03-30 | Vanguard Capital Management LLC | 6.15M | 151.79M | 3.85% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4.24M | 104.73M | 2.65% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 3.85M | 95.17M | 2.41% |
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.46M | 85.49M | 2.17% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 3.11M | 76.82M | 1.95% |
| 2026-05-30 | VANGUARD WORLD FUND-Vanguard U.S. Growth Fund | 3.04M | 75.00M | 1.90% |
| 2026-03-30 | T. Rowe Price Small-Cap Stock Fund, Inc. | 2.33M | 57.54M | 1.46% |